Xinmin Yu

机构：Zhejiang Cancer Hospital, Zhejiang Academy of Medical Sciences, Cancer Hospital of Chinese Academy of Medical Sciences, University of Chinese Academy of Sciences, Hangzhou Cancer Hospital

发表论文 79 篇 · 总被引 3114 次 · h-index 27

代表论文

• Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer (2021 · JAMA Oncology · 被引 410)
• Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study (2022 · Journal of Clinical Oncology · 被引 320)
• AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations (2022 · Journal of Clinical Oncology · 被引 302)
• Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial (2021 · Journal of Thoracic Oncology · 被引 292)
• Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China (2025 · The Lancet · 被引 167)
• Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy (2021 · Clinical Cancer Research · 被引 132)